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Table S1: Regulatory explanations of the term 'biosimilar' 
European Medicines 
Agency1 
A biosimilar is a biological medicinal product that contains a version of the 
active substance of an already authorised original biological medicinal product 
(reference medicinal product) in the EEA. Similarity to the reference medicinal 
product in terms of quality characteristics, biological activity, safety and 
efficacy based on a comprehensive comparability exercise needs to be 
established. 
 
U.S. Food & Drug 
Administration 2  
Biosimilar or biosimilarity means that ‘the biological product is highly similar 
to the reference product notwithstanding minor differences in clinically inactive 
components’ and that ‘there are no clinically meaningful differences between 
the biological product and the reference product in terms of the safety, purity, 
and potency of the product’.  
 
EEA- European Economic Area 
1 European Medicines Agency (2014) Guideline on similar biological medicinal products  
2 Section 7002(b) (3) of the Affordable Care Act, adding section 351(i) (2) of the Public Health Services Act 
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PK; pharmacokinetic, MS; multiple sclerosis 
 
  
Table S3: Substitution of biological medicines in Australia - Details of reference biological medicines and their biosimilars 
listed on the Australian Pharmaceutical Benefits Scheme (August 2018) 
Substance Products Substitution 
permitted 
(‘a’ flag status 
granted by 
PBAC)*. 









No  At time of authorisation Novicrit 
has restricted route of 







No  Absence of TGA statement that 
supports ‘a’ flagging 
 
[4, 6] 
Follitropin Alfa Gonal-f® 
Bemfola® 
No Substitution difficult from a 
practical perspective owing to 
differences in strengths, number of 
pens per pack and maximum 















No  No details provided on PBAC 
website 
[4] 
*’Brand equivalents are accompanied by an ‘a’ flag on the Pharmaceutical Benefits Schedule.  An ‘a’ flagged medicine 
may be substituted by a pharmacist at the point of dispensing. 
**Neulasta and Ristempa are not biosimilars but are the same products with different brand names  
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